

ASX Release

Top 20 Security Holders

PERTH, AUSTRALIA – 5 August 2020: SUDA Pharmaceuticals Ltd (ASX: SUD), a leader in oromucosal drug delivery, is pleased to announce the top 20 shareholders and option holders below.

Top 20 shareholders

Rank	Name	Units	% of Units
1	UBS NOMINEES PTY LTD	8,485,693	2.98
2	SCINTILLA STRATEGIC INVESTMENTS LIMITED	7,000,000	2.46
3	KAMALA HOLDINGS PTY LTD	6,600,000	2.32
4	BAMBER INVESTMENTS PTY LTD	4,316,184	1.52
5	SEMPAI INVESTMENTS PTY LTD	3,400,000	1.20
6	MR JAMES BRADLEY RICHARDSON	3,325,196	1.17
7	MR STEVE JOHN WICKS	3,036,572	1.07
8	ZERRIN INVESTMENTS PTY LTD	3,000,000	1.05
9	DYLIDE PTY LTD	3,000,000	1.05
10	MBANTUA HOLDINGS PTY LTD	3,000,000	1.05
11	MR PETER NORMAN DUNN	2,922,966	1.03
12	MR MARK ANDREW DUNCAN-SMITH	2,845,931	1.00
13	BANLAN PTY LTD	2,840,262	1.00
14	TADEA PTY LTD	2,600,000	0.91
15	MR KEVIN CLIFFORD BANKS + MRS JANNE PAMELA BANKS	2,552,332	0.90
16	MR STEVE JOHN WICKS	2,535,772	0.89
17	MR JAMES ANTHONY GOMEZ	2,422,528	0.85
18	MR BRETT MICHAEL BUSSELL + MRS JENELLE HELEN BUSSELL	2,401,082	0.84
19	MR DAVID CURZON SMITH + MRS DIANE MAURINE SMITH	2,286,891	0.80
20	TETS PTY LTD	2,250,000	0.79

Top 20 option holders (SUDOE)

Rank	Name	Units	% of Units
1	UBS NOMINEES PTY LTD	2,549,474	5.38
2	SCINTILLA STRATEGIC INVESTMENTS LIMITED	2,333,334	4.92
3	KAMALA HOLDINGS PTY LTD	1,533,334	3.23
4	ZERRIN INVESTMENTS PTY LTD	1,000,000	2.11
5	BAMBER INVESTMENTS PTY LTD	992,062	2.09
6	MR PETER NORMAN DUNN	949,334	2.00
7	SEMPAI INVESTMENTS PTY LTD	733,334	1.55
8	MR JAMES BRADLEY RICHARDSON	720,000	1.52
9	DYLIDE PTY LTD	666,667	1.41
10	TADEA PTY LTD	633,334	1.34
11	MR MARK ANDREW DUNCAN-SMITH	592,903	1.25
12	MR STEVE JOHN WICKS	562,762	1.19
13	MR DO SHIK HONG + MRS CHUN SOOK HONG	556,867	1.17
14	WERINGA NOMINEES PTY LTD	542,667	1.14
15	JATHRO PTY LTD	533,334	1.12
16	MR JAMES ANTHONY GOMEZ	533,333	1.12
17	MR BRADLEY DENNIS SCOTT	500,000	1.05
18	MBANTUA HOLDINGS PTY LTD	500,000	1.05
19	MR STEVE JOHN WICKS	489,296	1.03
20	BANLAN PTY LTD	473,377	1.00

Top 20 option holders (SUDOD)

Rank	Name	Units	% of Units
1	ZERRIN INVESTMENTS PTY LTD	1,300,000	6.28
2	MR BRETT MICHAEL BUSSELL + MRS JENELLE HELEN BUSSELL	1,177,973	5.69
3	MR BRADLEY THOMAS SLADE	1,050,000	5.08
4	MR BINH VAN TO	676,666	3.27
5	MR KONSTANTINOS BAGIARTAKIS	673,221	3.25
6	MR BARRY LAMBERT + MRS JOY LAMBERT	600,000	2.90
7	MR BRETT BUSSELL	561,200	2.71
8	M & K KORKIDAS PTY LTD	550,000	2.66
9	KAMALA HOLDINGS PTY LTD	548,666	2.65
10	SCINTILLA STRATEGIC INVESTMENTS LIMITED	533,333	2.58
11	ROOKHARP CAPITAL PTY LIMITED	500,000	2.42
12	MR DENNIS GREGORY SCOTT + MRS COLETTE THERESA SCOTT	450,000	2.18
13	CHELSEA INVESTMENTS (WA) PTY LTD	316,053	1.53
14	CHIEU VAN TRAN PTY LTD	300,000	1.45
15	MR ASRAF HADI BIN MOHD AKIR	267,857	1.29
16	MR JAMES BRADLEY RICHARDSON	250,000	1.21
17	BAMBER INVESTMENTS PTY LTD	247,023	1.19
18	MR JOHN BRIGHT	220,000	1.06
19	MR ROBERT BYRNE + MRS MICHELLE ANN BYRNE	213,333	1.03
20	MISS HOOI HOON KHOR	200,000	0.97

For and on behalf of the Board and for further information please contact:

Paul Hopper
Chairman
SUDA Pharmaceuticals Ltd
 Tel: +61 (0) 406 671 515
 phopper@sudapharma.com

Dr Michael Baker
Chief Executive Officer & Managing Director
SUDA Pharmaceuticals Ltd
 Tel +61 (0) 403 468 187
 mbaker@sudapharma.com

NOTES TO EDITORS:

About SUDA Pharmaceuticals Ltd

SUDA Pharmaceuticals Ltd (ASX: SUD) is a drug delivery company focused on oro-mucosal administration, headquartered in Perth, Western Australia. The Company is developing low-risk oral sprays using its OroMist® technology to reformulate existing pharmaceuticals. The many potential benefits of administering drugs through the oral mucosa (i.e.: cheeks, tongue, gums and palate) include ease of use, lower dosage, reduced side effects and faster response time. SUDA's product pipeline includes ZolpiMist™, a first-in-class oral spray of zolpidem for insomnia. ZolpiMist is marketed in the USA and SUDA has rights to the product outside of the US and Canada. Other products in development include oral sprays for the treatment of: migraine headache; chemotherapy-induced nausea and vomiting; erectile dysfunction; pulmonary hypertension; epileptic seizures and pre-procedural anxiety and cancer.

For more information, visit www.sudapharma.com